Bridger Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bridger Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-142,979	Closed	-$12.4M	–	33
2023 Q2	$12.4M	Hold	142,979	–	–	4.11%	12
2023 Q1	$13.9M	Buy	142,979 +540	+0.4%	+$56K	5.17%	8
2022 Q4	$14.7M	Buy	142,439 +42,039	+42%	+$3.95M	5.96%	7
2022 Q3	$8.51M	Sell	100,400 -107,400	-52%	-$9.56M	2.58%	16
2022 Q2	$17.2M	Buy	+207,800	New	+$16.5M	3.88%	10

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bridger Management's BMRN Position: Q3 2023 in Review

Bridger Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 142,979 shares — an estimated $12.4M sold.

Bridger Management first reported a position in BMRN in Q2 2022 and held it in 5 quarters. The position peaked at $17.2M in Q2 2022. 520 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Bridger Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Bridger Management sold 142,979 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $12.4M.
Bridger Management first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 5 quarters.
Bridger Management's BioMarin Pharmaceuticals position peaked at $17.2M in Q2 2022.
520 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Bridger Management's 13F filing for Q3 2023, filed 14 Nov 2023.